

antiviral and associated therapy - all results

| Treatment | Number of studies | clinical deterioration | clinical improvement | deaths | viral clearance |
|---|------------------------|--|--|---|--|
| chloroquine and derivatives | 4 studies ¹ | 0.93 [0.48 ; 1.81], 1 study, I2=0% inconclusive result | - | 0.84 [0.59 ; 1.20], 3 RCTs, I2=0% inconclusive result | - |
| ivermectin | 3 studies ² | - | 1.51 [0.54 ; 4.24], 1 RCT, I2=0% inconclusive result | 0.85 [0.50 ; 1.46], 2 RCTs, I2=0% inconclusive result | 0.52 [0.10 ; 2.58], 1 study, I2=0% inconclusive result |
| lopinavir/ritonavir | 2 studies ³ | - | 1.31 [0.94 ; 1.83], 1 RCT, I2=0% inconclusive result | 0.81 [0.65 ; 1.03], 2 RCTs, I2=0% inconclusive result | - |
| azithromycin | 1 study ⁴ | - | 0.74 [0.51 ; 1.07], 1 RCT, I2=0% inconclusive result | 1.08 [0.79 ; 1.47], 1 RCT, I2=0% inconclusive result | - |
| favipiravir | 1 study ⁵ | - | - | 1.61 [0.73 ; 3.58], 1 study, I2=0% inconclusive result | - |
| Lopinavir/ritonavir plus hydroxychloroquine | 1 study ⁶ | - | 0.63 [0.37 ; 1.06], 1 RCT, I2=0% inconclusive result | 0.58 [0.36 ; 0.93], 1 RCT, I2=0% certainty unassessable | - |
| remdesivir | 1 study ⁷ | 0.95 [0.55 ; 1.64], 1 RCT, I2=0% inconclusive result | 1.23 [0.87 ; 1.74], 1 RCT, I2=0% inconclusive result | 1.10 [0.49 ; 2.45], 1 RCT, I2=0% inconclusive result | - |
| sofosbuvir and daclatasvir | 1 study ⁸ | - | - | 0.12 [0.02 ; 0.62], 1 study, I2=0% certainty unassessable | - |

Notes

¹HYDRA (Hernandez-Cardenas), 2021 (NCT04315896); REMAP-CAP-HCQ, 2020 (NCT02735707); Mahevas, 2020 (); Yu, 2020 ()

²Galan, 2021 (RBR-8h7q82); Okumus, 2020 (NCT04646109); Camprubi, 2020 ()

³Cao, 2020 (ChiCTR2000029308); REMAP-CAP (lopinavir/ritonavir only), 2020 (NCT02735707)

⁴COALITION II Covid-19 Brazil (Furtado), 2020 (NCT04321278)

⁵Kocayigit H, 2020 ()

⁶REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 (NCT02735707)

⁷CAP-China (Wang et al.), 2020 (NCT04257656)

⁸Eslami, 2020 (IRCT20200324046850N2)